Medicare Enrolled
Dr. Michael McCleod, DO
Medical Oncology · Fort Myers, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. McCleod from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. McCleod? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. McCleod
Dr. Michael McCleod is a medical oncology in Fort Myers, FL, with 20 years in practice. Based on federal Medicare data, Dr. McCleod performed 118,427 Medicare services across 3,891 unique beneficiaries.
Between the years covered by Open Payments, Dr. McCleod received a total of $31,426 from 94 pharmaceutical and/or device companies across 1104 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McCleod is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 20% volume in FL$ $31,426 industry payments
Medicare Practice Summary
Medicare Utilization ↗118,427
Medicare services
Top 20% in FL for medical oncology
3,891
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,921 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 21,400 | $39 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 18,000 | $0 | $2 |
| Iron infusion (Feraheme) | 17,340 | $0 | $4 |
| Epoetin alfa injection (Procrit) for anemia | 16,100 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 11,220 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 7,670 | $1 | $5 |
| Immune globulin infusion (Gammagard) | 7,568 | $36 | $108 |
| Iron sucrose injection (Venofer) | 5,200 | $0 | $5 |
| Complete blood count (CBC) with differential | 2,294 | $8 | $29 |
| Blood draw (venipuncture) | 2,016 | $8 | $9 |
| Iron infusion (Monoferric) | 1,400 | $16 | $57 |
| Dexamethasone injection (steroid) | 1,159 | $0 | $3 |
| Office visit, established patient (20-29 min) | 942 | $65 | $239 |
| Drug injection, under skin or into muscle | 768 | $11 | $69 |
| Anti-nausea injection (Aloxi/palonosetron) | 661 | $1 | $28 |
| Office visit, established patient (30-39 min) | 579 | $100 | $339 |
| Injection, leucovorin calcium, per 50 mg | 522 | $3 | $12 |
| Anti-nausea injection (ondansetron/Zofran) | 436 | $0 | $9 |
| Injection of additional new drug or substance into vein | 425 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 417 | $96 | $378 |
| Injection, fluorouracil, 500 mg | 318 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 233 | $48 | $189 |
| Injection, diphenhydramine hcl, up to 50 mg | 217 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 198 | $22 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 172 | $16 | $56 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 137 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 123 | $22 | $84 |
| Infusion into a vein for hydration, each additional hour | 106 | $10 | $42 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 91 | $16 | $59 |
| Infusion, normal saline solution , 1000 cc | 78 | $2 | $7 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 72 | $25 | $89 |
| Administration of additional new drug or substance into vein, 1 hour or less | 69 | $49 | $178 |
| Injection, zoledronic acid, 1 mg | 69 | $6 | $69 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 59 | $57 | $206 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 53 | $129 | $562 |
| Infusion into a vein for hydration, 31-60 minutes | 50 | $24 | $156 |
| New patient office visit (30-44 min) | 50 | $74 | $298 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 40 | $140 | $637 |
| New patient office visit (45-59 min) | 38 | $136 | $453 |
| Injection of drug or substance into vein | 30 | $29 | $156 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 29 | $1 | $7 |
| Automated urinalysis | 27 | $2 | $8 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 18 | $3 | $11 |
| Drawing of blood for a medical problem | 17 | $66 | $277 |
| Red blood count automated, with additional calculations | 16 | $5 | $20 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.9% high complexity
71.9% medium
5.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$31,426
Total received (2018-2024)
Avg $4,489/year across 7 years
Top 18% in FL for medical oncology
94
Companies
1,104
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,654 (75.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$7,772 (24.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,900
2023$3,416
2022$3,529
2021$2,905
2020$2,078
2019$9,589
2018$6,009
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
F. Hoffmann-La Roche AG
$7,701
Novartis Pharmaceuticals Corporation
$1,740
E.R. Squibb & Sons, L.L.C.
$1,576
AstraZeneca Pharmaceuticals LP
$1,402
Incyte Corporation
$1,140
Janssen Biotech, Inc.
$1,001
PFIZER INC.
$879
GENZYME CORPORATION
$871
Genentech USA, Inc.
$869
Celgene Corporation
$857
Amgen Inc.
$819
Seagen Inc.
$778
Merck Sharp & Dohme Corporation
$709
Lilly USA, LLC
$654
Merck Sharp & Dohme LLC
$632
Exelixis Inc.
$570
Eisai Inc.
$490
BeiGene USA, Inc.
$452
Daiichi Sankyo Inc.
$434
JAZZ PHARMACEUTICALS INC.
$431
Clovis Oncology, Inc.
$341
GlaxoSmithKline, LLC.
$340
Foundation Medicine, Inc.
$330
Dova Pharmaceuticals
$313
Rigel Pharmaceuticals, Inc.
$304
EISAI INC.
$300
NanoString Technologies, Inc.
$262
Gilead Sciences, Inc.
$261
Bayer HealthCare Pharmaceuticals Inc.
$220
EMD Serono, Inc.
$215
Epizyme, Inc.,
$212
Bayer Healthcare Pharmaceuticals Inc.
$202
Astellas Pharma US Inc
$199
ADC Therapeutics America, Inc.
$194
TAIHO ONCOLOGY, INC.
$185
Janssen Scientific Affairs, LLC
$184
Boehringer Ingelheim Pharmaceuticals, Inc.
$181
Puma Biotechnology, Inc.
$180
Kite Pharma, Inc.
$176
PharmaEssentia USA Corporation
$164
CTI BioPharma Corp.
$164
Takeda Pharmaceuticals U.S.A., Inc.
$138
Dendreon Pharmaceuticals LLC
$128
Pharmacyclics LLC, An AbbVie Company
$126
BioMarin Pharmaceutical Inc.
$125
G1 Therapeutics, Inc.
$115
Alexion Pharmaceuticals, Inc.
$108
Veracyte, Inc.
$105
TerSera Therapeutics LLC
$97
Myovant Sciences Inc.
$97
Deciphera Pharmaceuticals Inc.
$84
CSL Behring
$83
Mirati Therapeutics, Inc.
$68
Taiho Oncology, Inc.
$68
Agios Pharmaceuticals, Inc.
$59
PUMA BIOTECHNOLOGY, INC.
$58
Seattle Genetics, Inc.
$56
MorphoSys, US Inc.
$54
Kyowa Kirin, Inc.
$54
Janssen Pharmaceuticals, Inc
$50
ARRAY BIOPHARMA INC
$47
AMAG Pharmaceuticals, Inc.
$44
Stemline Therapeutics Inc.
$43
EUSA Pharma (US) LLC
$43
SOBI, INC
$40
GE HEALTHCARE
$40
Acrotech Biopharma LLC
$34
Otsuka America Pharmaceutical, Inc.
$33
INSYS Therapeutics Inc
$30
Sumitomo Pharma America, Inc.
$29
SpringWorks Therapeutics, Inc.
$25
ABBVIE INC.
$25
Aurobindo Pharma USA, Inc.
$24
Jazz Pharmaceuticals Inc.
$24
Pharmacyclics LLC, an AbbVie Company
$23
Sysmex Inostics Inc
$23
TESARO, Inc.
$22
Acrotech Biopharma Inc.
$22
Spectrum Pharmaceuticals Inc.
$21
Secura Bio, Inc.
$20
AbbVie, Inc.
$20
Heron Therapeutics, Inc.
$19
Myriad Genetic Laboratories, Inc.
$19
AVEO Pharmaceuticals, Inc.
$18
Sobi, Inc
$17
Immunocore Limited
$16
Partner Therapeutics, Inc.
$16
BIOVERATIV THERAPEUTICS INC.
$14
Alnylam Pharmaceuticals Inc.
$14
Global Blood Therapeutics, Inc.
$13
Horizon Therapeutics plc
$12
Lexicon Pharmaceuticals, Inc.
$12
Helsinn Therapeutics (U.S.), Inc.
$11
Emmaus Medical, Inc.
$10
Top 3 companies account for 35.1% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aliqopa · Avastin · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · CEREZYME · CINVANTI · COSELA · CYRAMZA · Cabometyx · Cinvanti · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · ELOCTATE · ELREXFIO · EMPLICITI · ENHERTU · ERLEADA · Endari · Enhertu · Erleada · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · GAZYVA · GILOTRIF · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INREBIC · Idelvion · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MARQIBO · MEKINIST · MONJUVI · MVASI · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OCREVUS · OGSIVEO · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROSIGNA ASSAY · PROVENGE · PYRUKYND · Perjeta · Polivy · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RETEVMO · ROCTAVIAN · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SPRYCEL · SUTENT · SYNDROS · Stivarga · Sustol · Sylvant · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Tavalisse · Trodelvy · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XARELTO · XGEVA · XOSPATA · XTANDI · Xermelo · Xospata · Yescarta · ZEJULA · ZEPZELCA · ZEVALIN · ZOLADEX · ZYKADIA · ZYTIGA · Zevalin · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (75%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $27 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
11
Per 100K population
1.4
County median income
$73,099
Nearest hospital
LEE MEMORIAL HOSPITAL
8.0 mi
8.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McCleod is a mixed practice specialist, with above-average Medicare volume (top 20% in FL), and high industry engagement (low-engagement, top 18%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McCleod experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. McCleod performed 21,400 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. McCleod receive payments from pharmaceutical companies?
Yes. Dr. McCleod received a total of $31,426 from 94 companies across 1,104 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. McCleod's costs compare to other medical oncologys in Fort Myers?
Dr. McCleod's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. McCleod) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Fort Myers
Browse medical oncologys in Fort Myers ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
F. Hoffmann-La Roche AG Payments to Doctors
See all physicians who received payments from F. Hoffmann-La Roche AG.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology